MS drug in pregnancy: what happens to Baby's immune cells?

NCT ID NCT04998812

First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 28 times

Summary

This study looked at 70 pregnant women with multiple sclerosis or clinically isolated syndrome who took the drug ocrelizumab before or during early pregnancy. Researchers measured B cell levels in their babies to see if the drug crossed the placenta. The goal was to gather safety information, not to treat the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hopital Pierre Wertheimer - Hopital Neurologique

    Bron, 69003, France

  • Hosp. Clinico San Carlos

    Madrid, 28040, Spain

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Hôpital de la Pitié Salpétrière

    Paris, 75013, France

  • Inselspital Bern

    Bern, 3010, Switzerland

  • MultipEL Studies - Institut für klinische Studien

    Hamburg, 22179, Germany

  • St. Josef Hospital GmbH

    Bochum, 44791, Germany

  • The Ken and Ruth Davee department of Neurology

    Chicago, Illinois, 60611-4296, United States

  • University Of Colorado

    Aurora, Colorado, 80045, United States

  • University of California San Francisco

    San Francisco, California, 94158, United States

  • Universitätsspital Basel

    Basel, 4031, Switzerland

Conditions

Explore the condition pages connected to this study.